Table 8.
Base Case Economic and Health Result USA, Germany, and Italy
| sTTT | mTTT | LDA | |||||
|---|---|---|---|---|---|---|---|
| US | D | I | US | US | D | I | |
| Total cost per patient tested | 983 | 375 | 436 | 1051 | 573 | 243 | 270 |
| Testing | 13 | 10 | 19 | 10 | 40 | 39 | 44 |
| Treatment | 7 | 5 | 4 | 7 | 9 | 6 | 5 |
| Physician visit | 106 | 33 | 23 | 106 | 88 | 28 | 20 |
| AE management | 1 | 0 | 0 | 1 | 2 | 0 | 0 |
| Late disease management | 607 | 255 | 304 | 656 | 334 | 141 | 167 |
| Persisting Symptoms management | 250 | 72 | 85 | 271 | 100 | 29 | 34 |
| Total QALYs lost per patient tested due to LD | 0.042 | 0.042 | 0.042 | 0.045 | 0.018 | 0.018 | 0.018 |
| Early LD | – | – | – | – | – | – | – |
| Disseminated LD | 0.006 | 0.006 | 0.006 | 0.006 | 0.003 | 0.003 | 0.003 |
| Persisting symptoms | 0.036 | 0.036 | 0.036 | 0.039 | 0.014 | 0.014 | 0.014 |
| Total QALYs lost per infected patient due to LD | 0.323 | 0.323 | 0.323 | 0.350 | 0.136 | 0.136 | 0.136 |
| Early LD | – | – | – | – | – | – | – |
| Disseminated LD | 0.046 | 0.046 | 0.046 | 0.049 | 0.026 | 0.026 | 0.026 |
| Persisting symptoms | 0.277 | 0.277 | 0.277 | 0.300 | 0.111 | 0.111 | 0.111 |
Note: In bold, the most relevant economic and quality of life outcomes.
Abbreviations: LD, Lyme Disease; LDA, Lyme Detection Algorithm; sTTT, standard two-tier testing; mTTT, modified two-tier testing; ABX, antibiotic therapy; AEs, Adverse Events; US, United States of America; DE, Federal Republic of Germany; IT, Italian Republic; QALY, quality-adjusted life year.